Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
For full access to this article login to GEN Select now.
The Game Plan for Sigma's Research Biotech
Interview with David Smoller, Ph.D., New President of Firm's Research Biotech Unit
- David Smoller, Ph.D., recently was promoted to the helm of Sigma-Aldrich’s Research Biotech Business Unit (RBBU), one of four business units within the company. Dr. Smoller joined Sigma-Aldrich as vp, R&D, in 2004 after founding and selling two biotech start-up companies, Genome Systems and ProteoPlex. Dr. Smoller talked to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.